Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 20/20 | 0.79 |
| ▸ | HCRTR2 | O43614 | 20/20 | 0.79 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439578 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2CYP3A4HTR2A | |
| SCHEMBL440922 | 0.91 | HCRTR2 (0.65) | HCRTR1HCRTR2CYP3A4HTR2A | |
| SCHEMBL441256 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL2248574 | 0.83 | HCRTR2 (1.00) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL14907109 | 0.81 | HCRTR2 (0.80) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439583 | 0.81 | HCRTR2 (0.70) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL439572 | 0.81 | HCRTR2 (0.87) | HCRTR1HCRTR2CYP3A4HTR2A | |
| SCHEMBL439302 | 0.79 | HCRTR1 (0.73) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL441336 | 0.79 | HCRTR2 (0.83) | HCRTR1HCRTR2CYP3A4HTR2A | |
| SCHEMBL3486920 | 0.78 | HCRTR2 (0.83) | HCRTR1HCRTR2CYP3A4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438041-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-04-11 | — | — | EP | claimed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | claimed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | claimed |
| US-20120065394-A1 | Corrosion Inhibitors Having Increased Biodegradability and Reduced Toxicity | CLARIANT FINANCE (BVI) LIMITED (VG) | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010141275-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-12-09 | — | — | WO | disclosed |
| US-20100234592-A1 | Corrosion Inhibitors Having Increased Biodegradability and Reduced Toxicity | CLARIANT FINANCE (BVI) LTD. (VG) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234592-A1 | Corrosion Inhibitors Having Increased Biodegradability and Reduced Toxicity | C5, C9, CYP1A1 | HCRTR1 1541/4885HCRTR2 2583/4885CYP3A4 38/4885 |
| US-20120065205-A1 | PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY5R | HCRTR1 2/4885HCRTR2 1/4885CYP3A4 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.